Pharmacy Times 2008 OTC Products - (Page 27) THANK YOU GO BEYOND symptom relief of a cold sore. SOOTHE IT FAST Abreva’s base soothes on contact for making ABREVA the #1 Pharmacist recommended OTC cold sore medication† MOISTURIZING INGREDIENT Go beyond the usual OTC relief by recommending Abreva. Abreva soothes on contact. Its cream base contains a moisturizing ingredient. Below the lip surface however, it’s a different story. SKIN SURFACE INFECTED CELLS HSV-1 VIRUS HEAL IT FAST Abreva keeps the virus from penetrating healthy cells * Abreva contains serious medicine – Docosanol 10% – which has a unique Cell Entry Blocking Mode of Action. • Abreva works by modifying the lip cell’s membrane, helping to block the cold sore virus’s ability to fuse with the cell.1, 2* • Abreva’s mode of action can limit the virus’s ability to replicate, which can help to speed healing and reduce symptom duration.1** The sooner your patients start using Abreva (tingle stage), the better. For best results, recommend that patients use Abreva as early as possible, even up to and including the blister stage. PROTECTED CELLS HEALTHY CELLS Abreva is the only OTC medicine FDA approved to shorten both symptom duration and healing times. Abreva is now available in a unique pump dispenser that provides just the right amount of medicine in an easy to use, easy to carry format. © 2008 GlaxoSmithKline Consumer Healthcare * Based on laboratory studies ** Median healing = 4.1 days (p=0.008), Median time to complete symptom relief = 2.2 days (p=0.002) 1. Sacks SL et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol. 2001: 45:222-230 2. Pope LE et al. Anti-herpes simplex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug. Jnl Lipid Research V27, Issue 10, 1996: 2169-2178 † Pharmacy Times Annual Pharmacist recommendation Survey 2008 http://www.abreva.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.